Biotech
Vima Therapeutics
Vima Therapeutics raises $60M Series A at $280M valuation
$60M
Total Raised
Series A
Latest Round
2023
Founded
50+
Employees
Cambridge, MA
1 min read
Quick Facts
Valuation
$280M
Latest Round Size
$60M
Latest Round Date
May 2024
Vima Therapeutics: Series A Funding Round
Vima Therapeutics has successfully raised $60M in Series A funding, reaching a valuation of $280M.
Company Overview
Focused on oral therapies for movement disorders
Funding Details
The Series A round was led by Third Rock Ventures, with participation from Arch Venture Partners.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2023
- Employees: 50+
- Category: Biotech
Investment
Vima Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Third Rock Ventures: Verified investor in Series A
- Arch Venture Partners: Verified investor in Series A
Key Investors
Third Rock Ventures
Lead Investor
Verified investor in Series A
Arch Venture Partners
Investor
Verified investor in Series A
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
Editorial Team
Oct 8, 2025
1 min read•$153M